Alpha-erythropoietin in the treatment and prevention of anemia in patients with chronic kidney disease

Main Article Content

Ya.A. Dombrovskyi
M.D. Ivanova


The paper discusses current international recommendations on the diagnosis and treatment of anaemia in chronic kidney disease. Presents a detailed analysis of the alpha-erythropoietin, discussed the advantages and disadvantages of its application in clinical practice.

Article Details

How to Cite
Dombrovskyi, Y., and M. Ivanova. “Alpha-Erythropoietin in the Treatment and Prevention of Anemia in Patients With Chronic Kidney Disease”. KIDNEYS, no. 1.07, Feb. 2014, pp. 65-68, doi:10.22141/2307-1257.
To Help the Practitioner


Ermolenko V. M., Nikolaev, A. Y. Erythropoietin: biological properties and application in the clinic. Ter. archive. 1990;62(11):141-145.

Bauer С. Erythropoietin - from gene structure to therapeutic applications. J. Perinat. Med 1995;23:77-81.

Wu H., Lee S.H., Gao J. et al. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development. 1999;126:3597-3605.

Buemi M., Nostro L., Romeo A. From the oxygen to the organ protection: erythropoietin as protagonist in internal medicine. Cardiovasc Hematol Agents Med Chem. 2006;4(4):299-311.

Anagnostou A., Liu Z., Steiner M. et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A. 1994;91:3974-3978.

Ohneda O., Yanai N., Obinata M. Erythropoietin as a mitogen for fetal liver stromal cells which support erythropoiesis. Exp Cell Res. 1993;208:327-331.

Ogilvie M., Yu X., Nicolas-Metral V. et al. Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J Biol Chem. 2000;275:39754-39761.

Eckardt K.-U., Hartmann W., Vetter U. et al. Eur J Pediatr 1990; 149: 459-464.

Іванов Д.Д., Корж О.М. Нефрологія в практиці сімейного лікаря: навчально-методичний посібник. — 2-ге вид., переробл. — Донецьк: Видавець Заславський О.Ю., 2012. — 121-128 сс.

Клінічні практичні настанови KDIGO (2012) з анемії при ХХН//Почки.- 2013.- №1.- С.71-76.

Grimm C., Wenzel A., Acar N. et al. Hypoxic preconditioning and erythropoietin protect retinal neurons from degeneration. Adv Exp Med Biol. 2006;588:119-131.

Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ. 1990 Mar 3;300(6724):573-578.

Goldberg N., Lundin A.P., Delano et al. Changes in left ventricular size, wall thickness and function in anemic patients treated with recombinant human erythropoietin. Am Heart J. 1992;124:424-427.

Foley R.N., Parfrey P.S., Morgan J. et al. A randomized controlled trial of complete correction of anemia in hemodialysis patients with asymptomatic concentric LV hypertrophy or LV dilatation.

Mancini D. M., Katz S.D., Lang C.C. et al. Effect of Erythropoietin on Exercise Capacity in Patients With Moderate to Severe Chronic Heart Failure Circulation. 2003;107:294.

Van der Meer P., Lipsic E., Henning R.H. et al. Erythropoietin Induces Neovascularization and Improves Cardiac Function in Rats With Heart Failure After Myocardial Infarction. J Am Coll Cardiol, 2005;46:125-133.

Sowade O., Gross J., Sowade B. et al. Evaluation of oxygen availability with oxygen status algorithm in patients undergoing open heart surgery treated with erythropoietin beta. J Lab Clin Med 1997;129:97-105.

Jelkmann W. Renal erythropoietin: properties and production. Rev. Physiol. Biochem. Pharmacol. 1986;104:139-217

Pablo E. Pergola, Gary Gartenberg, Min Fu, Steven Sun, Marsha Wolfson, Peter Bowers A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoitin alfa in CKD patient with anemia.

Дударь И.А., Гончар Ю.И. Эффективность и безопасность препарата Эпобиокрин при коррекции анемии у пациентов с ХПН VD ст., которые находятся на заместительной гемодиализной терапии//Украинский журнал нефрологии и диализа.-2013.- №3 –С. 24-32.

Most read articles by the same author(s)

1 2 3 > >>